Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Novo Nordisk issued troubling guidance, projecting revenue could fall by as much as 13% for the current year; the stock has lost over 50% in the past 12 months and now trades around 10x earnings. The company faces pricing pressure and a CEO transition, but announced a distribution deal with Hims & Hers to sell GLP-1 products and has launched a Wegovy pill that may support future sales recovery.

Analysis

The market reaction looks driven more by expectation of durable margin compression and investor fear than by an immediate demand collapse; that creates a two-way liquidity event where any positive distribution or pricing news can produce outsized bounces. Telehealth partnerships (HIMS-style) are a lever that lowers patient acquisition costs and accelerates share-of-wallet but simultaneously commoditize channel pricing and put pressure on gross-to-net dynamics for incumbents.

Second-order winners will be digital-first dispensaries and vertically integrated telehealth outfits that can undercut traditional provider markup by 20–40% while capturing recurring refill economics; contract manufacturers and fill/finish partners face upside if incumbents pivot to price-led volume, but their margins will be capped by increased tendering. Payer behavior is the principal tail risk — aggressive formulary rebate demands or step edits can compress realized prices over 6–18 months, while regulatory scrutiny or broader clinical guidance changes could shorten the runway for premium pricing.

For portfolio construction, this is a classic dispersion opportunity: long scalable distribution plays with low fixed-cost models versus short incumbents facing both pricing and margin squeezes. Key catalysts to watch in the next 3–12 months are telehealth rollout KPIs (conversion, refill rate, CAC/LTV), quarterly realized price disclosure in company reports, and any payer contracting announcements that signal permanent net price resets.

Key Decisions for Investors

• Pair trade (6–12 months): Short NVO 1.0x notional / Long HIMS 1.0x notional. Rationale: capture relative margin compression in the incumbent vs accelerated customer acquisition and refill capture at HIMS. Target: relative gain +30% if NVO continues to derate and HIMS shows early volume lift; Stop-loss: relative loss -15% (rebase if NVO announces material buyback or major pricing reversal).
• Tactical options (9–12 months): Buy HIMS 12-month call spread to limit premium outlay (debit) — net delta exposure ~0.6. Rationale: leveraged bet on platform monetization and refill economics without outright equity risk. Target: 3:1 gross payoff to premium if telehealth KPIs exceed internal thresholds; Max loss = premium paid.
• Contrarian long (18–36 months): Initiate a core long NVO position sized for 6–8% of healthcare sleeve, financed by buying 9–12 month 10% OTM puts as downside protection. Rationale: if realized prices stabilize and share gains offset lower ASPs, rerating from 10x to 13–15x EPS is plausible. Target: +35–45% upside to fair-value rerate; protected downside to -20–25% net after put cost.
• Event hedge (0–3 months): Buy short-dated puts on NVO or tail-protect the fund's healthcare exposure ahead of the next quarterly report and any payer announcements. Rationale: hedges against near-term guidance disappointments that historically trigger >20% intraday moves. Cost threshold: keep hedge premium <0.5% of fund NAV for near-term protection.